Global Institute Of Stem Cell Therapy And Research

Category

Giostar News

Giostar Honored With Asian Heritage Award for Best in Business Category

Giostar Honored With Asian Heritage Award for Best in Business Category

DR. ANAND SRIVASTAVA AND DEVEN PATEL

Dr. Anand Srivastava and Deven Patel are co-founders of GIOSTAR (Global Institute of Stem Cell Therapy and Research), a leading stem cell therapy and research institute headquartered in San Diego. The company was founded to aid those suffering from debilitating health conditions such as Parkinson’s, Alzheimer’s, stroke, spinal cord injuries, cancer and diabetes. The company’s Regenerative Medicine program provides promise for treatments of diseases previously regarded as incurable.

Dr. Srivastava isregarded as a pioneer in the research of stem cell therapy and has long been associated with major academic and scientific institutions, including UCSD, UCLA and the Salk Research Institute. His work also extends to the research of cancer and gene therapy.

Recently, GIOSTAR Chairman Dr. Srivastava was invited to chair the session at the 8th Annual World Congress of Regenerative Medicine & Stem Cell-Korea. He has been
a frequent guest on numerous international conferences as the keynote speaker, presenter and on panels of experts. The speakers under his Chairmanship for this conference are the Who’s Who in the field of Stem Cell Science from the top universities around the world such as Cambridge and Oxford.

Mr. Patel’s role has been to take Dr. Srivastava’s research and create cell transplant programs with several state governments in India and to launch collaborative efforts with several other countries to establish treatment centers. Under his leadership, GIOSTAR has dedicated a state-of-the-art stem cell treatment hospital in Ahmedabad, India, and is planning additional facilities in China, Thailand, Dubai, the Philippines, Brazil, Sweden, Turkey and the Bahamas.

At GIOSTAR, Mr. Patel is in charge of developing stem cell transplant program for four different State Governments in India with total population of close to155 million. The four State Governments in Indi are preparing to treat their large, poor populations suffering from sickle cell anemia and thalassemia. GIOSTAR is in negotiations with China’s public and private sector to start stem cell transplant program at ten different locations.

Mr. Patel has served as the founding President of Asian and Pacific American Coalition (APAC), representing San Diego API communities from nine Asian countries and spearheaded its efforts in 2011 at City Hall to create the new 9th City Council District in City of San Diego to be an Asian Pacific American influenced district through the restricting process.

 

Source : http://goo.gl/35I4Ek

Giostar - Stem Cell Therapy

Stephen Hawking met with Mr. Deven Patel the CEO of San Diego based Global Institute of Stem Cell Therapy and Research (GIOSTAR) on Saturday to learn more about how soon stem cell research can help in his neurological disorder ALS (amyotrophic lateral sclerosis) that has left the famed British physicist completely paralyzed.

He was visiting San Diego to attend the private tree planting ceremony in memory of one of his oldest friends, the late San Diego philanthropist Dennis Avery.

Giostar CEO Mr. Deven Patel with Mr. Stephen Hawking

Giostar CEO Mr. Deven Patel with Mr. Stephen Hawking

Dr. Hawking spent more than hour with Mr. Patel in private meeting to learn the recent development in the field of stem cells, specially related to ALS, the condition British Physicist was diagnosed for almost five decades ago. “Even after his long afternoon event, he was very attentive to my stem cell presentation,” said Mr. Patel.

He had so many questions in his mind and he was very encouraged with the progress of the stem cell science in the field of neurology. Mr. Patel has requested his staff for his medical history to be studied by GIOSTAR team of scientists and clinicians.

With the advancement of stem cell science, our range of interests at GIOSTAR is expanding every single day. While our therapeutic programs are focused exclusively on the transplantation of tissue-derived (adult) stem cells and progenitor cells for several degenerative diseases of different organs, we believe there is a utility in all types of stem cells and their progeny.

Today GIOSTAR scientists study all three types of stem cells: tissue-derived stem cells, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, as well as progenitor cells. Molecular biology, genetic engineering and protein chemistry are core technologies for conducting this research. We consider all of these cell types as viable options both as cell-based therapies and as tools and technologies for drug discovery and development.

To speed up the transition from research to treatment, GIOSTAR has collaborated with the government of India to bring its treatment for sickle cell anemia to three states in the country serving some 150 million people in the world’s largest stem cell treatment hospital setting of its kind! In 2011 GIOSTAR has also inaugurated one of the world’s first dedicated stem cell treatment hospital in Ahmedabad, India. The company is developing plans for similar facilities in California as well as China, Thailand, Philippines, Dubai, Brazil, Sweden, Bahamas and few more worldwide locations.

The Chairman of GIOSTAR Dr. Anand Srivastava said, with the rapid progress in the field of stem cell science, we are not that far from the cures for many devastating diseases that are considered incurable today. “And If we can cure great human being like Dr. Stephen Hawking, this world certainly will be a better place to live,” he said.

Giostar - Stem Cell Therapy

Regenerative Medicine and Healthcare Risks: Risk Group Dialogue with Deven Patel

While a big-data revolution is under way in health care, there is also another silent revolution brewing in healthcare industry in the form of Regenerative Medicine.

In this session of Risk Roundup, Risk Group discusses Regenerative Medicine and Healthcare with GIOSTAR CEO Mr. Deven Patel, CEO, President & Cofounder at Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A.

GIOSTAR CEO Mr. Deven Patel Visits Saudi Arabia

 

 

 

 

 

Gujarat awarded Prime Minister’s Civil Services Award for successfully tackling Sickle Cell Anemia in Gujarat

Sickle Cell Anaemia is the most common form of Sickle Cell Disease (SCD). SCD is a serious disorder in which the body makes sickle-shaped red blood cells. Sickle-shaped means that the red blood cells are shaped like a crescent. In Gujarat, this disease is prevalent in certain tribes. The State Government under the leadership of Honble Chief Minister is committed to improve the lives of marginalized people and weaker sections of society to bring them at par with rest of the people of the State. As a part of improving the lives of people especially tribals and in a bid to control the menace of disease which affects a very large tribal population of the state, the Government has taken various measures and also decided to set up Gujarat Sickle Cell Control Society. The Sickle Cell Anaemia Control Programme was started in four districts of South Gujarat in the year 2006 at the behest of Honble Chief Minister Shri Narendra Modi. The programme was later expanded to all 12 tribal districts of the State. Initially, 78 Government and NGO Institutions were involved in the programme from 4 tribal districts of South Gujarat. As of December 2010, there were 414 centres across the 12 tribal districts of that were involved in the comprehensive care of SCA patients.

The Government has taken up the challenging task of Mass Sickle Cell Screening of all 61.62 lakh tribal population of Gujarat within 5 years at a cost of Rs.24.76 crore. The Government of Gujarat also signed a MoU with GIOSTAR, a USA based company for creating stem cell faculties at the Government Medical College, Surat. Under this programme, more than 13 lakh tribal people benefited during last four years. This is an unique and a highly focused programme to tackle the problem of Sickle Cell Anemia in the tribal population of the State. A multi-pronged and comprehensive strategy was adopted. They were also provided necessary counseling. Marriage counseling was also done amongst youngsters. As a result, tremendous awareness is noticeable amongst tribal people of Gujarat by way of their participation in prenatal diagnosis and new born screening program, thereby reducing morbidity and mortality as a result of this genetic disorder. In fact, to improve the lives of tribal people and bring them at par with rest of the population in the State, Honble Chief Minister has launched a Rs.15,000 crore Van Bandhu Yojana for implementation during 11th Five Year Plan (2007-2012). During last 10 years, Gujarat is acknowledged as a State which has planned and implemented a number of excellent initiatives which have solved the problems of the State and these initiatives have become model for rest of the country. Some of the schemes/models have been recognized internationally by Commonwealth and United Nations.

Source

Health Sector Attracts MoUs worth over Rs 7,000 cr at Vibrant Gujarat Summit

Health sector attracts MoUs worth over Rs 7,000 cr at Vibrant Gujarat summit

The health sector, which was rather ignored at the last Vibrant Gujarat Global Investors’ Summit (VGGIS), has attracted Memoranda of Understanding (MOUs) worth Rs 7,231.26 crore as against Rs 800 crore signed in the previous summits. The number of MOUs signed in this sector shot up from eight in 2007 to 32 this year, the highest till date. Dr J Awasia, the Deputy Director of Medical Sciences, said: “Apart from a huge upswing in the number of projects signed, quite a few number of interesting projects have come up this time.” The GIOSTAR Global Institute for Stemcell Therapy Treatment MoU was signed for a 2-billion dollar investment, bringing home the much-awaited stem-cell treatment that promises to bring hope for many diseases in one go. Among the promising projects signed at the summit are the setting up of a 5,000-bed super specialty private hospital by the Narayan Rutiulaya Pvt Ltd, which will equal the proposed capacity of the Ahmedabad Civil Hospital, which is to be upgraded under the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY). The Quality Council of India has come up with a project to assess and upgrade the quality standards of the rural health institutes like the Primary Health Centres (PHCs) in the state.

The Rs 5-crore project will see investment undertaken by the government, with the Quality Council of India providing technological cooperation. Joint Secretary (Health) Mona Khadar, said: “The first of its kind Naturopathy Treatment Centre at Anand has been signed by the Nisarg Hospital. Naturopathy is an emerging area in the state. This project is worth Rs 7 crore.” A Rs 2-crore Homoeopathic Hospital to be set up by the M L Dhavle Memorial Homoeopathy Institution will be an addition to the homoeopathy treatment services in the state. Medical education has successfully grabbed the attention of investors. The Ahmedabad Municipal Corporation (AMC) will set up a dental and a medical college (150 seats each) attached to the L G Hospital (Sheth Lallubhai General Hospital) at the closed Balakiya Mills site. The Adani Education Research Foundation has entered an MoU to set up a 150-seat medical college in Bhuj. The Gujarat Cancer Society will also set up a 150-seat medical college in Ahmedabad at a cost of Rs 100 crore. Of the eight MoUs signed at the previous summit, two have been dropped and another two are reportedly complete. The remaining four projects are under process. The 32 MoUs in the health sector this time look promising. With the government announcing 60 per cent of the implementation, compared to the RTI documents showing only 25 per cent, at least investment of Rs 180 crore is expected to flow in.

 

Source

Make An Enquiry

We are here to help you

WordPress Video Lightbox